The genetic mutations underlying treatment resistance in non-small cell lung cancer (NSCLC) are more complex and dynamic than previously thought. Analysis of 355 biopsied tumors from patients who ...
Integrating HER2-directed therapies into NSCLC decision-making requires adapting protocols and ensuring timely updates as new therapies emerge. Streamlined processes and enhanced communication among ...
Blood-based circulating tumor DNA (ctDNA) testing has proven to be insufficient for detecting KRAS mutations in patients with low-grade serous ovarian cancer (LGSOC), according to a study. The ...
Agilus Diagnostics has launched an automated molecular diagnostics platform capable of detecting key cancer-related genetic mutations within 2.5 to 3 hours, reducing the time required for biomarker ...
Dr. Angie DeMichele and Dr. Lynn Henry present the latest rapid recommendation impacting two ASCO guidelines. This update focuses on testing for ESR1 mutations in patients with hormone ...
Certain genetic mutations can boost your risk of breast cancer. Here’s what experts say you need to know when making the decision to get tested. Possible anomalies in a breast cancer screening are ...
The prothrombin gene mutation increases your risk of severe blood clots. Medications, regular checkups, and healthy lifestyle habits can help reduce this risk. The prothrombin gene plays a crucial ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results